重庆市新生儿高胆红素血症患儿G6PD基因突变类型及临床特点

目的研究重庆市新生儿黄疸儿G6PD三种常见基因突变与其临床表现特点之间的关系。初步估计其基因突变频率并探讨其临床意义和遗传学特征。方法应用突变特异性扩增系统(ARMS)法,检测54例重庆市新生儿黄疸儿的G6PD基因突变类型。结果检出G1388A突变39例(72%),G1376T突变8例(15%),未定型者7例(13%)。未检出G95A。结论本研究首次对重庆市新生儿黄疸儿进行G1388A、G1376T和A95G突变检测。提示G1388A和G1376T为重庆市新生儿黄疸儿G6PD缺乏症基因突变的主要类型。ARMS法是一种简便、快速、经济的检测G6PD已知基因突变的方法。本研究发现这两种突变类型仅见于中国人和华裔人群,具有遗传学及临床意义。     

Smith-Fineman-Myers综合征的候选基因GPC4分析

目的:探讨GPC4基因与中国山东Smith-Fineman-Myers综合征(SFMS)的关系,并分析SFMS患者GPC4基因突变。方法:利用primer3设计扩增GPC4全部编码序列及内含子和外显子接头序列的引物,采用PCR扩增结合PCR产物直接测序方法检测GPC4基因开放性阅读框架区域基因突变。结果:在GPC4基因开放性阅读框架区域内并未检测到导致疾病的基因突变。结论:山东SFMS家系患者不是由于GPC4基因编码区域基因突变所致。     

A clinical and genetic study of 56 Saudi Wilson disease patients: identification of Saudi-specific mutations

Wilson disease (WD) is a hereditary disorder, with recessive transmission and genetic heterogeneity. Several mutations of ATP7B, the gene underlying WD, were reported in many ethnic groups. In this study, mutation screening in ATP7B of 56 Saudi Arabian WD patients was undertaken. The clinical data of all patients were recorded. The entire ATP7B coding sequence, including intron-exon boundaries were screened for mutation by the polymerase chain reaction (PCR)-based mutation detection technique and DNA sequencing. Thirty-nine patients were symptomatic at presentation and 17 subjects were pre-symptomatic siblings of affected patients. Fourteen patients had neurological, 11 patients had mixed (hepatic and neurological), and 14 patients had hepatic presentations. Family history suggestive of WD was present in 72% of cases and 68% had consanguineous parents. Genetic analysis showed disease-causing mutations in three exons (exons 8, 19 and 21) of the ATP7B gene in 28 patients (50%). Mutations in exons 21 (18 cases) and 19 (one case) were unique for Saudis. This large series of Saudi patients with WD has shown wide variability in the genomic substrate of WD. There is no correlation between genotype and clinical presentation.     

荧光偏振检测HBV DNA C区BCP双突变

目的：建立简便、灵敏的HBV DNA序列中BCP双突变点的检测方法．方法：采用终点终止法和偏振光检测技术进行点突变的检测．首先对HBV C区基因进行PCR扩增，然后用特异探针与扩增产物中待测核苷酸的下游序列杂交，使探针的3’端可以在DNA聚合酶的催化下，依据其互补链上的待测核苷酸连接上一个标有特定荧光素的ddNTP，然后检测该3’端带有荧光素的探针，根据检测到的荧光素种类和偏振光的强度可以判定待测点是何种核苷酸．结果：该方法可以检测出HBV基因序列中BCP双突变核苷酸类型以及检测1个拷贝的模板，并且可以从BCP野性株DNA序列中检出5％BCP双突变DNA序列．结论：该技术可以检测血清中HBV DNA C区BCP双突变．     

G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.

Among mutations associated with autosomal dominant and sporadic Parkinson's disease (PD) the G2019S substitution in the leucine-rich repeat kinase 2 (LRRK2) gene is the most frequently identified. To estimate its frequency in Russia, we analyzed 208 patients with PD from the Northwestern region of Russia. Of these, 51 patients were probands from families with PD compatible with autosomal dominant inheritance. The control group represented 161 subjects without neurological disorders settled in the same region. The frequency of the G2019S mutation was greater in familial PD (2 [3.9%] of 51) than in sporadic PD (1 [0.6%] of 157). In addition, this mutation was found in the proband's father, who also had PD, in 1 PD family, and in 1 carrier without signs of PD at age 40 in another PD family. All carriers were heterozygous for the G2019S mutation and reported the Ashkenazi Jewish origin. The mutation was not found in the control group.     

遗传性痉挛性截瘫paraplegin基因的突变分析

目的探讨paraplegin基因在中国人遗传性痉挛性截瘫(HSP或SPG)中的突变特点,为该病的基因诊断奠定基础。方法应用聚合酶链反应单链构象多态性(PCRSSCP)结合DNA序列分析方法,对来自全国8个常染色体隐性遗传HSP家系的先证者和14例散发性HSP患者进行paraplegin基因突变分析。结果所有外显子均可扩出,发现15号外显子上2例先证者出现异常SSCP条带,经DNA序列分析发现2063及2066位点上存在碱基G被A替换,但家系内不存在共分离的现象,且正常对照者也存在G被A替换,考虑为多态,其中G2066A为首次发现。结论Paraplegin基因突变可能在中国人HSP患者中少见。2063G→A及2066G→A是paraplegin基因的两个多态性改变,其中2066G→A为首次发现。     

人心肌肌钙蛋白I第2和第4个密码子同义突变对其在大肠埃希菌中表达的影响

目的 对人心肌肌钙蛋白I（cTnI）基因实行定点突变并进行原核表达，观察此突变对cTnI表达量的影响。方法 利用RT-PCR方法从人心肌细胞的总RNA中克隆出编码人心肌肌钙蛋白I的cDNA片段，设计引物将其第2和第4个密码子突变后插入原核表达载体形成重组体，并导人宿主菌BL21（DE3）中，经IPTG诱导表达，Ni-NTA树脂纯化后行Western blot鉴定，观察突变对cTnI表达的影响。结果 突变后的cTnI基因与对照组相比在大肠埃希菌中得到高效表达，经纯化可获得电泳单点纯的cTnI蛋白。结论 成功克隆了cTnI基因，所设计的同义突变可促进cTnI在大肠埃希菌中的高效表达。     

Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene.

Parkin mutations account for the majority of familial and sporadic early onset Parkinson's disease (EOPD) cases with a known genetic association. More than 100 mutations have been described in the Parkin gene that includes homozygous, compound heterozygous, and single heterozygous mutations. We have designed a Parkin mutation genotyping array (gene chip) that includes published Parkin sequence variants and allows their simultaneous detection. The chip was validated by screening 85 PD cases and 47 controls previously tested for Parkin mutations. Similar genotyping microarrays have been developed for other genetically heterogeneous diseases including age-related macular degeneration. Here, we show the utility of a genotyping array for Parkinson's disease by analysis of 60 subjects from the Genetic Epidemiology of Parkinson Disease (GEPD) study that includes 15 early-onset PD case probands and 45 relatives.     

肝移植后单一拉米夫定干预下HBV再感染及其相关因素分析

目的　探讨在单一拉米夫定 (LMV)干预下乙型肝炎相关性肝病肝移植后HBV再感染的发生 ,并分析其发生的易感因素。方法　随访 1999～ 2 0 0 3年接受肝移植并采用单一LMV防治HBV再感染的 6 3例乙肝相关性肝病患者 ,术后定期进行乙肝标志物、肝功能及HBVDNA定量检测 ,调查HBV再感染发生率并采用Logistic回归分析方法就术前诊断、病毒学资料及抗病毒治疗等分析其可能的易感因素。结果　在不同时期共出现HBV再感染 17例 ;各时间段HBV再感染率分别是 :6个月内9.5 % (6 / 6 3,其中 5例术后HBV标志物一直未阴转 ) ,6个月～ 1年 13.2 % (7/ 5 3) ,1～ 2年 2 7.8% (10 /36 ) ,2～ 3年 4 1.2 % (7/ 17) ,3年以上 6 0 .0 % (3/ 5 ) ;患者术前HBVDNA阳性及长期服用LMV与术后再感染呈正相关 (P <0 .0 5 ) ,而术前诊断、性别、年龄及血清HBsAg和HBeAg状态与HBV再感染则未发现显著相关性。结论　单一LMV预防HBV再感染对大多数肝移植者仍有效 ,但随术后存活时间的延长HBV再感染率呈现上升 ;术前使HBVDNA阴转及建立针对LMV耐药性变异的监测对防治再感染是必要的。